IDEAYA, Gilead To Evaluate Efficacy, Safety Of IDE397+Trodelvy Combination, Stock Up In Pre-Market

(RTTNews) - IDEAYA Biosciences, Inc. (IDYA), Thursday announced an additional clinical study collaboration and supply agreement with Gilead Sciences, Inc. (GILD) to evaluate the efficacy and safety of IDE397, in combination with the latter's Trodelvy in methylthioadenosine phosphorylase or MTAP-deletion non-small cell lung cancer or NSCLC.

The company explained that IDE397 is a potent and selective small molecule inhibitor targeting methionine adenosyltransferase 2a or MAT2A, in patients having solid tumors with MTAP-deletion.

IDEAYA expects to provide updates regarding Phase 1/2 trial evaluating IDE397 in combination with Trodelvy in 2025.

Additionally, the precision medicine oncology company IDEAYA is actively enrolling patients into a monotherapy expansion in MTAP-deletion NSCLC and urothelial cancer, and is set to initiate a wholly-owned clinical combination trial of IDE397 and IDE892 in the second half of 2025.

In the pre-market hours, IDEAYA's stock is climbing 3.78 percent, to $22.78 on the Nasdaq.